RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing InnoCare Pharma is planning a Hong Kong IPO that could raise as much as $250 million and value the company at a minimum of $800 million, according to informed sources. InnoCare is still early in the process and has not yet chosen investment bankers for the offering. The company, which is developing immunotherapies for cancer and autoimmune diseases, has three molecules in or near clinical trials, including its lead product, a BTK inhibitor that is currently being tested in multiple Phase II trials for cancer.
Source: China Biotoday
